ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

ClinicalTrials.gov ID: NCT03667690

Public ClinicalTrials.gov record NCT03667690. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 5:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection vs. Intravenous Caspofungin Followed by Oral Fluconazole Step Down in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

Study identification

NCT ID
NCT03667690
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Enrollment
199 participants

Conditions and interventions

Interventions

  • Caspofungin Drug
  • Fluconazole Drug
  • Rezafungin for Injection Drug
  • intravenous placebo Drug
  • oral placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 6, 2018
Primary completion
Oct 6, 2021
Completion
Oct 6, 2021
Last update posted
Jan 5, 2023

2018 – 2021

United States locations

U.S. sites
19
U.S. states
14
U.S. cities
19
Facility City State ZIP Site status
University of Alabama Birmingham Alabama 35294
UC Davis Sacramento California 95817
Emory University Hospital Atlanta Georgia 30322
Augusta University Augusta Georgia 30912
Johns Hopkins Baltimore Maryland 21287
Henry Ford Health System Detroit Michigan 48202
University of Minnesota Minneapolis Minnesota 55455
Mayo Clinic Hospital-Rochester Rochester Minnesota 55902
University of Mississippi Medical Center Jackson Mississippi 39216
Washington University St. Louis St Louis Missouri 63110
Mecury Street Medical Butte Montana 59701
University of North Carolina Chapel Hill North Carolina 27514
Duke University Medical Center Durham North Carolina 27710
ID Clinical Research, Ltd. Toledo Ohio 43608
University of Pittsburgh Falk Medical Center Pittsburgh Pennsylvania 15213
Reading Hospital and Medical Center West Reading Pennsylvania 19611
The University of Texas Health Science Center at San Antonio San Antonio Texas 78229
Baylor Scott and White Medical Center Temple Texas 76508
Carilion Clinic Roanoke Virginia 24014

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 113 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03667690, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 5, 2023 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03667690 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →